Peptide PilotPeptide Pilot

Vial duration

Ipamorelin vial duration calculator

Estimate how many weeks one 2 mg Ipamorelin vial covers at your dose and weekly cadence.

Download Peptide PilotiPhone · Free to download

Total doses

10

Lasts

1.4 weeks

Ipamorelin is a short-acting injectable peptide people use to trigger a clean pulse of their own growth hormone, usually for recovery, sleep, and body composition. It mimics the gut hormone ghrelin at a single receptor, which keeps GH release pulse-like and avoids meaningful spikes in cortisol or prolactin. Studies show clear short-term GH increases after each injection, which is why it's commonly stacked with CJC-1295. This page covers reconstitution math and per-injection logging cadence.

How the Ipamorelin vial duration calculator works

This calculator answers the inventory question: at your current dose and weekly cadence, how many weeks will this Ipamorelin vial last? It is the math you need to plan refills before a vial runs dry mid-protocol — especially with peptides like GLP-1s where shipping windows can run several weeks.

The formula is two divisions. Total doses per vial equals vial mg divided by dose mg, rounded down. Weeks of supply equals total doses divided by doses per week. With a 2 mg vial of Ipamorelin, a 0.2 mg dose, and 7 dose per week, the vial covers 10 doses, or about 1.4 weeks of supply.

The three inputs that move the answer: vial mg (set when you bought the vial), dose mg (set by your protocol step), and doses-per-week (set by the peptide's half-life). Once a vial is reconstituted it also has a stability ceiling — most lyophilized peptides reconstituted in BAC water are typically used within four to six weeks of refrigerated storage, so a vial that mathematically lasts twelve weeks may not last twelve weeks in practice.

Use this calculator before opening a new vial to confirm the dose and cadence you have planned will not strand you halfway through. Use it again whenever you titrate up — a dose increase shortens vial life, sometimes dramatically. The calculator is intentionally conservative: it floors total doses, never assumes partial-dose draws, and never extends weeks beyond what whole doses support.

Ipamorelin cadence and how it changes vial life

Research protocols often schedule Ipamorelin administration to coincide with the body's natural growth hormone pulses, such as late in the evening before sleep or following strenuous exercise. Cadence in these studies frequently involves daily administration, as seen in the 7-day-per-week example. To ensure precision, doses are measured using U-100 insulin syringes, which allow for accurate volume control when drawing from a reconstituted vial. For optimal signaling, doses are typically administered on an empty stomach to avoid the inhibitory effects of insulin and somatostatin on GH release.

The rationale for stacking Ipamorelin with a Growth Hormone-Releasing Hormone (GHRH) analog, such as CJC-1295 without DAC, is based on creating a powerful synergistic effect. This combination targets two distinct but complementary receptors in the pituitary gland: Ipamorelin activates the ghrelin receptor, while the GHRH analog activates its own receptor. Activating both pathways simultaneously has been studied to amplify the magnitude of the resulting GH pulse far more than either compound could alone, while still preserving the natural pulsatile pattern of release.

Research protocols designed to study ipamorelin often schedule administrations around specific metabolic states, particularly fasting. Because elevated blood glucose and subsequent insulin secretion can attenuate the GH pulse stimulated by GHS-R agonists, many study designs plan for administration in a fasted state, such as in the morning before any caloric intake or at least two to three hours after the last meal. By standardizing the prandial state, researchers can better control for variables that influence GH release. All such details, including the duration of the pre-administration fast, can be meticulously documented in a log to observe patterns with greater clarity.

Storage and shelf life for Ipamorelin

Lyophilized Ipamorelin powder awaiting reconstitution is stored in a refrigerated environment to maintain its integrity. Once reconstituted with a sterile diluent like bacteriostatic water, the vial containing the solution is also kept under refrigeration. The in-use solution is generally monitored over a planned period of use that typically spans several weeks.

Tracking Ipamorelin vials in a real log

For anyone documenting an Ipamorelin protocol, the most critical variable to log is the exact timing of each dose. The selectivity advantage of this peptide is best observed by analyzing trends over multiple weeks, and this analysis is only valid if dose timing is consistent. Inconsistent scheduling can introduce confounding variables that make it difficult to evaluate the protocol's adherence. When Ipamorelin is part of a stack, such as with CJC-1295, each compound must be recorded as a separate entry in the log to permit accurate inventory tracking and ensure the remaining quantity in each vial is known.

For those engaged in detailed personal data collection, logging the prandial state at the time of each ipamorelin administration provides a critical layer of information. Beyond simply recording the date, time, and dosage, adding a note such as 'Fasted >3 hours' or 'Post-prandial <90 minutes' creates a more robust dataset. Over time, these records allow an individual to analyze and observe any correlations between administration timing relative to meals and the tracked outcomes. This level of detail enables a more sophisticated review of the data, helping to identify patterns that might otherwise be obscured by metabolic variables like insulin levels.

Common Ipamorelin vial-planning mistakes

  • Administering doses at inconsistent times of day, which compromises the ability to observe long-term trends related to its selective action.
  • Logging a combination like Ipamorelin/CJC-1295 as a single dose entry, which inevitably causes errors in vial inventory management for each separate peptide.
  • Misinterpreting the designed absence of an appetite spike as a sign that the peptide is inactive or low in potency.
  • Scheduling administration shortly after a meal containing carbohydrates or fats, thereby blunting the potential GH pulse via insulin release.
  • Failing to document the reconstitution date and diluent volume, which makes future dose calculations and expirations impossible to track accurately.
  • Assuming ipamorelin produces identical secondary hormonal effects as older compounds like GHRP-6, thereby failing to account for its selective nature in study design.
  • Not documenting the timing of administration in relation to meals, which introduces insulin fluctuations as an uncontrolled variable.
  • Neglecting to use a calculator to verify dose calculations after reconstitution, leading to inconsistent administration amounts that compromise data integrity.

Frequently asked questions about Ipamorelin vial duration

What is the primary distinction between Ipamorelin and GHRP-6?
The defining distinction is selectivity. Ipamorelin was developed specifically to stimulate growth hormone release with high potency while avoiding the significant increases in appetite, cortisol, and prolactin that are characteristic of older secretagogues like GHRP-6. This targeted action results from its refined molecular structure and specific binding profile.
Why is Ipamorelin often studied in combination with CJC-1295 without DAC?
This combination is studied because it targets two separate pituitary receptors to synergistically amplify GH release. Ipamorelin acts on the ghrelin receptor while CJC-1295 (no DAC) acts on the GHRH receptor. Activating both pathways at once generates a more robust GH pulse than using either peptide alone, while still honoring the body's natural pulsatile rhythm.
How many units are required for a 200 mcg dose from a 2 mg vial reconstituted with 2 mL?
A 2 mg vial holds 2,000 micrograms of peptide. When reconstituted with 2 mL of bacteriostatic water, the final concentration becomes 1,000 mcg per mL. To draw a 200 mcg dose, you need 0.2 mL of the solution, which measures as exactly 20 units on a U-100 insulin syringe.
Does Ipamorelin's smaller peptide structure influence its properties?
Yes, its structure as a pentapeptide makes it one of the smallest molecules in the GHRP class. This minimalism is a key element of its design, contributing to its high binding specificity for the ghrelin receptor and its 'clean' profile, which minimizes the off-target receptor interactions seen with larger, more complex secretagogues.
Is the lack of a hunger response a sign that Ipamorelin is not working?
No, the absence of hunger is a designed-in feature and a direct confirmation of Ipamorelin's selectivity. It successfully uncouples the GH-releasing action from the separate ghrelin-mediated hunger signaling that is a hallmark of GHRP-6. The peptide's activity is determined by its effect on GH levels, not by the presence or absence of secondary effects.
What is the significance of scheduling doses in a fasted state?
Administering Ipamorelin on an empty stomach is a standard element of research protocols because the presence of food, especially carbohydrates and fats, can trigger the release of insulin. Insulin can in turn stimulate somatostatin, a hormone that inhibits growth hormone secretion from the pituitary. Dosing in a fasted state avoids this potential blunting effect on the GH pulse.
Why is ipamorelin administration often timed around fasting in research settings?
Many research protocols document ipamorelin administration during a fasted state due to the interaction between insulin and growth hormone. The GH pulse stimulated by ipamorelin can be partially blunted by elevated insulin levels, which typically occur after consuming a meal, especially one rich in carbohydrates. To study its effects under consistent physiological conditions, researchers often schedule administrations at times when insulin levels are expected to be at a baseline, such as upon waking or several hours after a meal. Logging the prandial state at the time of administration is a way to track this variable.
What specifically makes ipamorelin a 'selective' GH secretagogue?
Ipamorelin is considered selective because it was specifically designed to stimulate growth hormone release with minimal to no effect on other hormones like cortisol and prolactin at standard research dosages. Its development by Novo Nordisk in the 1990s aimed to improve upon earlier GHRPs, which were observed to cause elevations in these other hormones. This selectivity allows researchers to study the effects of GH elevation in a more isolated manner, without the confounding variables of simultaneous increases in stress hormones or prolactin.
Does the selectivity of ipamorelin change with the dose amount?
In scientific literature, the selectivity of ipamorelin for the GH axis is often noted as being dose-dependent. While standard research doses are observed to have minimal impact on cortisol and prolactin, studies involving very high, supramaximal doses have sometimes documented a loss of this selectivity. This means that at extremely large dosages, some stimulation of cortisol and prolactin might be observed. Therefore, when researchers plan a study, the dosage is a critical parameter to control and document, as it directly relates to the compound's selective properties.

Related on Peptide Pilot

Track Ipamorelin vials automatically

Download on the App Store
Get the App